Virginia Clinical Trials Report — June 2026

For Virginians considering participation in clinical research, June 2026 presents both urgent opportunities and exciting new avenues to contribute to medical science. Across the Commonwealth, a significant number of studies are nearing their enrollment deadlines, meaning time is of the essence for those interested in participating. Currently, 123 clinical trials are slated to close within the next 90 days, with 14 of these actively seeking healthy volunteers.

This critical window offers a chance to join research that could impact future treatments for a range of conditions. Individuals living with specific health challenges should particularly note the trials with impending deadlines. Conditions with studies closing soon include:

• Advanced solid tumor
• Heart failure
• Ovarian cancer
• Endometrial cancer
• Non-small cell lung cancer (NSCLC)
• Cancer (general)
• Breast cancer
• Duchenne muscular dystrophy
• Colorectal cancer
• Dementia

If you or a loved one are affected by these conditions, exploring these trials immediately could provide access to investigational treatments before they close to new participants.

New Research Frontiers Open Across Virginia

This month, Virginia welcomes 31 new clinical trials, marking a slight increase from the 29 trials that opened in May 2026. These new studies span a diverse range of health areas and intervention types, with a strong presence from major pharmaceutical sponsors and academic institutions. The new trials are distributed across 1,024 research sites in 67 cities, contributing to the total of 1,849 trials currently recruiting statewide.

Among the most notable new trials are several large-scale Phase 3 drug studies from well-known sponsors, offering participants access to cutting-edge research for prevalent health issues and important public health initiatives:

• Pfizer is leading two significant Phase 3 vaccine trials focused on pneumococcal disease. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims to enroll 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Complementing this, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children and adolescents.
• For those with type 2 diabetes mellitus, AstraZeneca is sponsoring two major Phase 3 studies. NCT07662109, "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus," plans for 2,000 participants to evaluate a new combination therapy. Additionally, NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," will enroll 1,200 participants to compare a new drug with an existing treatment for type 2 diabetes.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants. This study aims to assess the efficacy and safety of a new acute migraine treatment.
• A unique and ambitious initiative, NCT07661823, "QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project)," sponsored by Veterans Recovery Network Inc., is seeking a remarkable 1,000,000 participants. This study explores whether a quantum artificial intelligence (AI) public health agency can provide free or low-cost behavioral and mental health services within self-contained communities.
• For bladder cancer detection and surveillance, NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform," sponsored by Convergent Genomics, Inc., is a prospective observational study aiming for 2,500 participants to collect biospecimens and clinical data.
• Finally, NCT07623902, "Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population," sponsored by Jubaan Ltd., seeks 1,436 participants to evaluate a new device for identifying colorectal pre-cancer or cancer in average-risk adults with a negative Fecal Immunochemical Test (FIT).

Diverse Conditions and Interventions in Focus

The 31 new trials launched this month in Virginia address a broad spectrum of health conditions, reflecting ongoing research priorities. Metabolic health and cancer research are particularly prominent. The most common conditions targeted by these new studies include:

• Obesity (3 trials)
• Type 2 diabetes mellitus (2 trials)
• Overweight (2 trials)
• Breast cancer (2 trials)
• Pneumococcal disease (2 trials)

In terms of research approach, drug trials continue to dominate, accounting for 15 of the new studies. Other intervention types include behavioral interventions (3 trials), medical devices (4 trials), biological treatments (2 trials), and diagnostic tests (1 trial), demonstrating a comprehensive effort to advance medical knowledge and care.

Geographic Accessibility: Research Hubs Across Virginia

Virginia's clinical research landscape is robust, with new opportunities emerging across the state. This month, the majority of new research initiatives are concentrated in key metropolitan areas, ensuring accessibility for many residents. The cities with the highest number of new trials include:

• Richmond (11 new trials)
• Norfolk (5 new trials)
• Charlottesville (4 new trials)
• Newport News (3 new trials)
• Roanoke (3 new trials)
• Fairfax (3 new trials)

Additional new trials have opened in Lynchburg (2), Burke (1), Virginia Beach (1), and Falls Church (1). This distribution highlights that while major cities like Richmond and Norfolk serve as significant research hubs, opportunities are also expanding into other regions, making it easier for Virginians from various communities to participate.

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 31 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 136 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research without a diagnosed illness.

Clinical trials in Virginia are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 7 include children as participants, and 25 include older adults, ensuring that research benefits diverse age groups. Additionally, 4 new trials are specifically for female participants, and 1 is male-only. Academic institutions like Virginia Commonwealth University (3 new trials) and the University of Virginia (2 new trials) continue to play a vital role, alongside industry sponsors such as AstraZeneca (4 new trials), Novo Nordisk A/S (2 new trials), Pfizer (2 new trials), and Kallyope Inc. (2 new trials), driving significant research efforts across the state.

As we move through June, the focus remains on advancing medical understanding and patient care through these diverse and impactful clinical trials. We encourage all interested Virginians to explore these opportunities, especially those with impending deadlines, to contribute to the future of health.